Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2026 Jul;40(7):641-646;652. doi: 10.13201/j.issn.2096-7993.2026.07.008.
ABSTRACT
Objective:To evaluate the efficacy of Stapokibart in patients with chronic rhinosinusitis with nasal polyps（CRSwNP） based on key type 2 inflammatory clinical characteristics. Methods:A total of 28 patients with CRSwNP receiving either stapokibart or placebo were stratified based on peripheral blood eosinophil（EOS） count（cutoff value: 0.3×10⁸/L）, comorbid asthma, and history of sinus surgery. After 24 weeks of treatment, changes from baseline in efficacy endpoints-including nasal polyp score（NPS）, nasal congestion score（NCS）, loss of smell score（LOS）, total nasal symptom score（TNSS）, 22-item Sino-Nasal Outcome Test（SNOT-22）, University of Pennsylvania Smell Identification Test（UPSIT）, and Lund-Mackay CT score were analyzed within each subgroup and compared against the placebo group. Results:After 24 weeks of treatment, stapokibart demonstrated significant improvements in nasal symptoms and related outcome measures across all subgroups compared to placebo. Due to the reduced sample sizes following subgroup stratification, differences in efficacy within each subgroup did not reach statistical significance. Conclusion:Stapokibart is effective in the overall CRSwNP population. However, whether its efficacy is influenced by factors such as comorbid asthma, eosinophil levels, or surgical history warrants validation in larger cohort studies.
PMID:42402683 | DOI:10.13201/j.issn.2096-7993.2026.07.008
